197 related articles for article (PubMed ID: 25261291)
21. A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany.
Link H; Thompson SF; Tian M; Haas JS; Meise D; Maas C; Dimitrov S
Support Care Cancer; 2022 Nov; 30(11):9317-9327. PubMed ID: 36076105
[TBL] [Abstract][Full Text] [Related]
22. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.
Meza LA; Green MD; Hackett JR; Neumann TA; Holmes FA
Pharmacotherapy; 2003 Nov; 23(11):1424-31. PubMed ID: 14620389
[TBL] [Abstract][Full Text] [Related]
23. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
24. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
25. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
[TBL] [Abstract][Full Text] [Related]
26. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Kosaka Y; Rai Y; Masuda N; Takano T; Saeki T; Nakamura S; Shimazaki R; Ito Y; Tokuda Y; Tamura K
Support Care Cancer; 2015 Apr; 23(4):1137-43. PubMed ID: 25576433
[TBL] [Abstract][Full Text] [Related]
27. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
Ip EJ; Lee-Ma A; Troxell LS; Chan J
Am J Health Syst Pharm; 2008 Aug; 65(16):1552-5. PubMed ID: 18693211
[TBL] [Abstract][Full Text] [Related]
28. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
Shi YK; Chen Q; Zhu YZ; He XH; Wang HQ; Jiang ZF; Chang JH; Liu YP; Wang AL; Luo DY; Zhang Y; Ke XY; Li WL; Zhang WJ; Wang XW; Zhang YP; Wang JM; Liu XQ
Anticancer Drugs; 2013 Jul; 24(6):641-7. PubMed ID: 23571496
[TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Harbeck N; Lipatov O; Frolova M; Udovitsa D; Topuzov E; Ganea-Motan DE; Nakov R; Singh P; Rudy A; Blackwell K
Future Oncol; 2016 Jun; 12(11):1359-67. PubMed ID: 27020170
[TBL] [Abstract][Full Text] [Related]
30. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
Park KH; Sohn JH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Hong DS; Park S; Shin SH; Kwon HC; Seo JH
Invest New Drugs; 2013 Oct; 31(5):1300-6. PubMed ID: 23677653
[TBL] [Abstract][Full Text] [Related]
31. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Schwartzberg LS; Bhat G; Peguero J; Agajanian R; Bharadwaj JS; Restrepo A; Hlalah O; Mehmi I; Chawla S; Hasal SJ; Yang Z; Cobb PW
Oncologist; 2020 Aug; 25(8):e1233-e1241. PubMed ID: 32476162
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy.
Zou L; Buchner A; Roberge M; Liu PM
J Immunol Res; 2016; 2016():9248061. PubMed ID: 27419145
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
Kubo K; Miyazaki Y; Murayama T; Shimazaki R; Usui N; Urabe A; Hotta T; Tamura K
Br J Haematol; 2016 Aug; 174(4):563-70. PubMed ID: 27072050
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.
Volovat C; Gladkov OA; Bondarenko IM; Barash S; Buchner A; Bias P; Adar L; Avisar N
Clin Breast Cancer; 2014 Apr; 14(2):101-8. PubMed ID: 24485296
[TBL] [Abstract][Full Text] [Related]
35. Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.
Volovat C; Bondarenko IM; Gladkov OA; Elsässer R; Buchner A; Bias P; Müller U
Springerplus; 2015; 4():316. PubMed ID: 26155455
[TBL] [Abstract][Full Text] [Related]
36. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.
Spunt SL; Irving H; Frost J; Sender L; Guo M; Yang BB; Dreiling L; Santana VM
J Clin Oncol; 2010 Mar; 28(8):1329-36. PubMed ID: 20142595
[TBL] [Abstract][Full Text] [Related]
37. Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
Barrett JA; Greene D; Lakshmikanthan S; Kolli P; Chawla S; Lebel F
J Clin Pharmacol; 2021 Feb; 61(2):204-210. PubMed ID: 32827162
[TBL] [Abstract][Full Text] [Related]
38. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
39. Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.
Li Y; Klippel Z; Shih X; Wang H; Reiner M; Page JH
Cancer Chemother Pharmacol; 2016 Apr; 77(4):703-12. PubMed ID: 26886017
[TBL] [Abstract][Full Text] [Related]
40. A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
Sohn BS; Jeong JH; Ahn JH; Jung KH; Kim JE; Sohn JH; Koh SJ; Seo JH; Lee KS; Kim SB
Invest New Drugs; 2020 Jun; 38(3):866-873. PubMed ID: 31728715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
